AbbVie beats Q2 revenue, adjusted EPS estimates but cuts FY adj EPS guidance
ABBV•Guidance lowered for 2026 adjusted EPS
AbbVie updated its 2026 adjusted diluted EPS guidance to $13.87-$14.07 from $13.91-$14.11.
The company said the Apogee acquisition is expected to be $0.14 per share dilutive to 2026 EPS. AbbVie said its 2026 EPS guidance includes a $0.58 per share unfavorable impact from acquired IPR&D.
Portfolio performance and analyst coverage
- Immunology growth - Higher Skyrizi and Rinvoq sales drove immunology portfolio revenue up 15%, offsetting a steep decline in Humira.
- Neuroscience expansion - Neuroscience portfolio revenue rose 20%, led by Vraylar, Botox Therapeutic and migraine treatments.
- Oncology and aesthetics weakness - Oncology revenue declined 1.5% and aesthetics grew only 0.3%, with Imbruvica and Juvederm sales falling.
Key details:
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Net Revenue | Beat | $16.99 bln |
